- Home
- ALT vs PRLD Comparison
ALT vs PRLD Comparison
Compare ALT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | PRLD |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.8M | 529.1M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALT | PRLD |
|---|---|---|
| Price | $3.11 | $5.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $17.67 | $5.67 |
| AVG Volume (30 Days) | ★ 4.5M | 468.8K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | $41,000.00 | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.00 | 73.43 |
| 52 Week Low | $2.56 | $0.98 |
| 52 Week High | $6.44 | $6.83 |
Technical Indicators
Market Signals| Indicator | ALT | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 59.55 |
| Support Level | $2.80 | $3.75 |
| Resistance Level | $3.32 | N/A |
| Average True Range (ATR) | 0.14 | 0.52 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 73.17 | 61.50 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.